Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1399 • ACR Convergence 2025
Significance of Antiphospholipid Antibodies in Patients with Sjogren’s Disease
Rashmi Thimmapuram¹, Ahmad Alkhatib², Joshua Baker³, Mehrdad Maz⁴ and Ghaith Noaiseh², ¹University of Kansas Medical Center, Westwood, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Pennsylvania, Philadelphia, PA, ⁴The University of Kansas Medical Center, Kansas City, KS
Background/Purpose: A few reports have evaluated the frequency of antiphospholipid antibodies (aPL) in Sjogren’s disease (SjD) and their association with SjD or Antiphospholipid Antibody Syndrome…
Abstract Number: 1382 • ACR Convergence 2025
Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis
Delia Reina¹, Paula Estrada-Alarcón², Daniel Roig-Vilaseca¹, Dacia Cerdà¹, Vanessa Navarro-Angeles³, oscar Camacho¹, Sergi Herdia⁴, Marta lópez-Gómez¹, Silvia Gacía-Díaz¹, Paola Vidal Montal⁵, Pol Maymó-Paituvi⁶, martí Aguilar-Coll⁷ and Javier Narváez⁸, ¹Complex Hospitalari Universitari Moisès Broggi, Barcelona, Spain, ²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ³Department of Rheumatology, Complex Universitari Hospitalari Moisès Broggi, Sant Joan Despí, Barcelona, Spain, Sant Joan Despí, Barcelona, Spain, ⁴Complex Hospitalari Moisès Broggi, Barcelona, Spain, ⁵Bellvitge University Hospital, Barcelona, Spain, ⁶Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitari de Bellvitge, L'Hospitalet; Barcelona, Barcelona, Spain
Background/Purpose: Sjögren’s disease (SjD) is a chronic autoimmune disorder primarily targeting exocrine glands. A significant extraglandular manifestation is interstitial lung disease (ILD), which contributes to…
Abstract Number: 0518 • ACR Convergence 2025
Deregulation of PSGL-1, HLA-DR and IFNα expression in peripheral innate immune cells of primary Sjögren Syndrome patients
Santos Castañeda¹, Alejandra Ramos-Manzano², Ines Sanchez-Abad³, Miren Uriarte-Ecenarro⁴, M. Paula Alvarez-Hernandez⁴, Esther San-Antonio⁴, Esther Vicente-Rabaneda⁵ and Ana Urzainqui⁴, ¹Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ²Hospital Unversitario de la Princesa, Madrid, Madrid, Spain, ³Hospitla de la Princesa, Madrid, Spain, ⁴Hospital de la Princesa, Madrid, Madrid, Spain, ⁵Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease characterized by lymphocytic infiltration of exocrine glands and systemic manifestations including cutaneous and renal involvement. Phagocytes--monocytes,…
Abstract Number: 2298 • ACR Convergence 2025
When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
kyung-Ann Lee¹, Yeonhee Kim¹, Se Hee Kim² and Hyun-Sook Kim³, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Kyung Hee University College of Medicine, Seoul, Republic of Korea, ³Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea
Background/Purpose: Salivary gland ultrasound (SGUS) and minor salivary gland biopsy (MSGB) are widely used in the diagnosis of primary Sjögren’s syndrome (pSS). However, discordance between…
Abstract Number: 1881 • ACR Convergence 2025
Silent Impact: Two Decades of Sjögren’s Syndrome Mortality in the United States
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², MD Walid Akram Hussain², Reshma John², Elvira Assaf², Amer Al Badawy², Barbare Khatiashvili², Rouba Isshak², John Salama², Ibrahim Sabah² and Robert Lahita³, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Sjögren’s syndrome is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands with potential systemic involvement. Despite its known complications, population-level mortality…
Abstract Number: 1398 • ACR Convergence 2025
Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
R. Mohamad Javier¹, Bernadus Bramantyo², Arkan Berlian³, Mahardika Nugraha⁴, Azzura Simanulang¹, Eko Setyo Herwanto⁵, Athaya Febriantyo Purnomo⁶, Jonathan Jonathan⁷, Ananingati Ananingati⁵, Budi Prakoso⁸ and Aisyah Rizki Nirmala Hanum⁵, ¹University of Indonesia Hospital, Jakarta Selatan, Jakarta Raya, Indonesia, ²Sardjito General Hospital, Daerah Istimewa Yogyakarta, Yogyakarta, Indonesia, ³Dr. Cipto Mangunkusumo Hospital, Jakarta Barat, Jakarta Raya, Indonesia, ⁴Universitas Islam Sultan Agung, KOTA SEMARANG, Jawa Tengah, Indonesia, ⁵Universitas Muhammadiyah Malang, Malang, Jawa Timur, Indonesia, ⁶Saiful Anwar General Hospita, Malang, Jawa Timur, Indonesia, ⁷RSUD Kalideres, Jakarta, Jakarta Raya, Indonesia, ⁸Department of Internal Medicine, RST dr Soepraoen, Malang, Jawa Timur, Indonesia
Background/Purpose: Autoimmune rheumatic diseases such as Sjögren’s Syndrome (SS) and Systemic Sclerosis (SSc) can significantly impact reproductive health and increase maternal cardiovascular risk. These conditions…
Abstract Number: 1381 • ACR Convergence 2025
Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
Caterina Di Pede¹, Alessandro Colitta², Marco Di Galante³, Simone Bruno⁴, Stefano Donati¹, Beatrice Dei¹, Giovanni Fulvio¹, Gaetano La Rocca⁵, Rosaria Talarico⁶, Marta Mosca¹, Chiara Baldini⁷ and Ugo Faraguna⁴, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Toscana, Italy, ³Sleepacta srl, Montacchiello, Pisa, Italy, Pisa, Toscana, Italy, ⁴Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa., Pisa, Toscana, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ⁶Azienda Ospedaliero Universitaria Pisana, Pisa, Pisa, Italy, ⁷University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Patients with Sjögren’s Disease (SjD) frequently report debilitating symptoms such as pain, fatigue, and dryness, significantly impacting health-related quality of life. Although sleep disturbances…
Abstract Number: 0517 • ACR Convergence 2025
Gut Microbiota Dysbiosis and Clinical Predictors of Fatigue in Primary Sjögren’s Syndrome: A Multi-Omics Study
Qiguo Cui¹, Pan Wang², Bin Zhou¹ and QIn Huang³, ¹Southern Medical Univercity Nanfang Hospital, guang zhou, China (People's Republic), ²southern medical university Nanfang Hospital, Guangzhou, China (People's Republic), ³Nanfang Hospital, Guangzhou, China (People's Republic)
Background/Purpose: Fatigue affects 70% of primary Sjögren's syndrome (pSS) patients, but its mechanisms remain unclear. We investigated clinical predictors and gut microbiota associations in pSS-related…
Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Matt Makara, Casey Hogan
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
Abstract Number: 2296 • ACR Convergence 2025
Evaluation of the Dual Mode of Action of Ianalumab (VAY736) in the Circulation and Salivary Gland Tissue of Patients With Sjögren’s Disease: Results From a Phase 2 Mechanistic Study
Divi Cornec¹, Rainer Hillenbrand², Patrice Hemon³, Diego Saldana Miranda², Marion Le Rochais⁴, Aida Santos Da Costa², Marie Frutoso³, Cristian Iperi⁵, Ulrike Sommer², Arnaud Uguen⁴, Christophe Jamin⁴, Patricia Baley⁶, Caroline Denis⁶, Dewi Guellec⁴, Alice Tison⁴, Daniel Strasser², sandrine jousse⁴, Shuqi Chen⁷, Noemi Giglioli², CAROLE SIPS², Alain SARAUX⁸, Richard Siegel⁹, Wolfgang Hueber¹⁰, Sophie Hillion⁴, Valerie Devauchelle¹¹ and Claire Bonal², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ²Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ³LBAI, UMR¹²²⁷, University of Brest, Brest, France, Brest, France, ⁴LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ⁵LBAI, UMR¹²²⁷, University of Brest, Brest, France, Basel, France, ⁶CHU Brest, Brest, France, Brest, France, ⁷China Novartis Institutes for BioMedical Research, Shanghai, China, Shangai, China (People's Republic), ⁸CHU Brest, Brest, France, ⁹Novartis Biomedical Research, Basel, Switzerland, ¹⁰Novartis Pharmaceuticals, Basel, Switzerland, ¹¹UBO, Brest, France
Background/Purpose: Ianalumab, a glycoengineered, fully human, IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions via a dual mechanism…
Abstract Number: 1684 • ACR Convergence 2025
Integration of Multiple Spatial Transcriptomics Reveals Novel Insights into Sjogren Disease Salivary Gland Fibroblast by Peripheral Serostatus
Zhou Fang¹, Ahmet Coskun¹ and Sara McCoy², ¹Georgia Tech, Atlanta, ²University of Wisconsin–Madison, Madison, WI
Background/Purpose: Anti-SSA antibody positive (SSA+ [Ro52 or Ro60]) and negative (SSA-) Sjögren disease (SjD) have differing clinical phenotypes and prognostic features; however, the pathogenesis driving…
Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Raúl Menor Almagro⁷, Belén Serrano-Benavente⁸, Judit Font-Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesús Alberto Garcia Vadillo¹², Ruth Lopez-Gonzalez¹³, Javier Narváez¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Juan Gonzalez Martin¹⁷, Paloma Vela Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, Beatriz Paredes-Romero²¹, Leyre Riancho-Zarrabeitia²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Herdia²⁵, Clara Moriano²⁶, Mª Angeles Blazquez Cañamero²⁷, Paula Estrada-Alarcón²⁸, Enrique Judez²⁹, Nerea Alcorta-Lorenzo³⁰, Consuelo Ramos Giraldez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁸Hospital Gregorio Marañon, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Regional Universitario Málaga, Malaga, Spain, ¹²Hospital Universitario La Princesa, Madrid, Spain, ¹³Zamora Health Complex, Salamanca, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹La Paz University Hospital, Alcalá De Henares, Spain, ²⁰Dr Negrin University Hospital, Ls Palmas, Spain, ²¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²²Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²³¹² de Octubre University Hospital, Madrid, Spain, ²⁴Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²⁵Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁶Hospital León, LEON, Castilla y Leon, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Spain, ²⁸Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁹Albacete University Hospital, Albacete, Spain, ³⁰Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
Abstract Number: 1380 • ACR Convergence 2025
Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach
Beatrice Dei¹, Stefano Donati¹, Gaetano La Rocca², Giovanni Fulvio¹, Federico Fattorini¹, Antonello Sulis¹, Michele Moretti¹, Elena Elefante¹, Francesco Ferro³, Giulia Ricci⁴, Marta Mosca⁵ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ³Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ⁴Neurology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Neuropathic pain (NeP) is increasingly recognized as a relevant symptom domain in primary Sjögren’s disease (SjD), contributing to the disease burden beyond glandular involvement.…
Abstract Number: 0515 • ACR Convergence 2025
Inverse Correlation Between Type I Interferon Pathway Activation And Unstimulated Whole Salivary Flow In Sicca Patients
Nikolaos Marketos¹, Charalampos Skarlis¹, Sylvia Raftopoulou¹, Ada Gjyrezi², Paul Zumbo³, Doron Betel³, Ioanna E. Stergiou⁴, Michael Voulgarelis⁴, Paraskevi Giannakakou⁵ and Clio Mavragani⁶, ¹Molecular Physiology and Clinical Applications Unit, Department of Physiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Department of Physiology , National & Kapodistrian University of Athens, Athens, Greece, New York, ³Department of Physiology & Biophysics, Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA, New York, ⁴Outpatient Rheumatology Clinic, Department of Pathophysiology, Medical School of Athens, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁵Department of Medicine, Weill Cornell Medicine, New York, NY, USA, and Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA, New York, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Oral and ocular dryness are hallmarks in patients with Sjögren’s disease (SjD). Given that activation of interferon (IFN) pathways has been shown to be…
Abstract Number: 2665 • ACR Convergence 2025
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Thomas Dörner¹, Nan Shen², Thomas Grader-Beck³, Caroline Walter⁴, Catherine Wioland⁴, Celine Rauld⁴, Patrick Schmutz⁴, Simone Riek⁴, Wolfgang Hueber⁵, CAROLE SIPS⁶, Stephen Oliver⁴, Carol Lau⁷, Claire Bonal⁶ and Isabelle Isnardi⁸, ¹Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ²Shanghai Jiang Tong University School of Medicine, Shanghai, China (People's Republic), ³Johns Hopkins, Reisterstown, MD, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Pharmaceuticals, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, ⁸Novartis, Gueberschwihr, France
Background/Purpose: Ianalumab, an afucosylated mAb, depletes B cells via enhanced antibody (Ab)-dependent cellular cytotoxicity and blocks B cell-activating factor (BAFF): BAFF-receptor (BAFF-R) mediated signals.1 It…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].